AI Financial Corp

ALT5 Sigma Corporation provides blockchain-powered technologies globally through its Fintech and Biotechnology segments. The company's Fintech operations involve the tokenization, trading, clearing settlement, payment, and safe keeping of digital assets. Key products in this segment include ALT 5 Prime, an electronic over-the-counter trading platform for buying and selling digital assets, and ALT 5 Pay, a cryptocurrency payment gateway that allows merchants to accept and make cryptocurrency payments or integrate the platform into their applications. In its Biotechnology segment, ALT5 Sigma Corporation focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies for pain and addiction treatment. This includes the development of JAN 101, an oral and sustained-release pharmaceutical composition of sodium nitrite that has completed Phase 2a clinical trial to treat peripheral arterial disease and pain, and JAN123, a formulation of low-dose naltrexone for the treatment of chronic regional pain syndrome. The company, founded in 1976, was formerly known as JanOne Inc. and changed its name to ALT5 Sigma Corporation in July 2024. It is based in Las Vegas, Nevada.